CellFE’s platform enables efficient multiplex CRISPR-Cas9 editing to engineer T cells
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
News
Categories
15 Results for ""
CellFE Closes Series Seed Funding Round
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.
CellFE to Participate in NIIMBL Funded Project
CellFE will participate in one of 15 funded projects as part of $9M in funding by the National Institute for Innovation in Manufacturing Biopharmaceuticals…